General Information of Drug (ID: DM5I2HL)

Drug Name
GSK269962A Drug Info
Synonyms GSK-269962A; GSK269962; GSK 269962; GSK-269962; aminofurazanyl-azabenzimidazole 6n
Indication
Disease Entry ICD 11 Status REF
Inflammation 1A00-CA43.1 Clinical trial [1]
Cross-matching ID
PubChem CID
16095342
CAS Number
CAS 925213-63-4
TTD Drug ID
DM5I2HL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
KD025 DM548TK Psoriasis vulgaris EA90 Phase 2 [2]
INS-117548 DMA46DO Glaucoma/ocular hypertension 9C61 Phase 1 [3]
PMID28048944-Compound-19 DMPT3V9 N. A. N. A. Patented [4]
PMID28048944-Compound-3 DM1BN74 N. A. N. A. Patented [4]
PMID28048944-Compound-7 DMXZ368 N. A. N. A. Patented [4]
PMID28048944-Compound-4 DMJAUWG N. A. N. A. Patented [4]
PMID28048944-Compound-5 DMAB987 N. A. N. A. Patented [4]
PMID28048944-Compound-6 DM5RCBV N. A. N. A. Patented [4]
PMID28048944-Compound-2 DM9ZXOP N. A. N. A. Patented [4]
Tricyclic compound 7 DME84S5 N. A. N. A. Patented [4]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Netarsudil DM0LPI9 Open-angle glaucoma 9C61 Approved [5]
SAR-407899 DMF95KD Diabetic nephropathy GB61.Z Phase 2 [6]
H-1152 DM8XH3S Pulmonary arterial hypertension BB01.0 Phase 2 [7]
INS-117548 DMA46DO Glaucoma/ocular hypertension 9C61 Phase 1 [3]
PMID28048944-Compound-19 DMPT3V9 N. A. N. A. Patented [4]
PMID28048944-Compound-3 DM1BN74 N. A. N. A. Patented [4]
PMID28048944-Compound-7 DMXZ368 N. A. N. A. Patented [4]
PMID28048944-Compound-4 DMJAUWG N. A. N. A. Patented [4]
PMID28048944-Compound-5 DMAB987 N. A. N. A. Patented [4]
PMID28048944-Compound-6 DM5RCBV N. A. N. A. Patented [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Rho-associated protein kinase 1 (ROCK1) TTZN7RP ROCK1_HUMAN Inhibitor [1]
Rho-associated protein kinase 2 (ROCK2) TTGWKQJ ROCK2_HUMAN Inhibitor [1]

References

1 Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.
2 Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814-9.
3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4 Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
5 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
6 The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012 May;30(5):980-9.
7 Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.